Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
    (Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
    (Date:8/28/2014)... Earlier this month, a report was ... the U.S. Air Force on the performance of vehicles ... this type of fuel made from mustard seeds, offered ... to America’s Eco friendly future. In fact, every branch ... become independent of foreign oil over the next few ...
    (Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 ... Pipette.com is offering a promotion for Eppendorf ... Pipette.com customers to purchase the highest quality tubes ... Tubes are ideal for customers doing chemical, medical, ... lab technicians who are not regularly able to ...
    Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
    ... PARK, N.C., Jan. 29 ,Merial Limited and Chimerix, Inc. ... Merial will screen a Chimerix chemical library for,animal health ... has an,option to negotiate a license with Chimerix for ... with Chimerix provides us with an opportunity to,further expand ...
    ... in cash at year end; no equity financings expected ... disease programs to continue in,2008; latest data for all ... - Expansion of research and development investment ... lysosomal diseases in 2008, CRANBURY, N.J., Jan. 29 ...
    ... 29 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has received conditional approval from the U.S.,Food ... the U.S. pivotal,clinical trial of the Edwards SAPIEN transcatheter ... the Ascendra transapical,delivery system to the trial, and also ...
    Cached Biology Technology:Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 3
    (Date:8/29/2014)... MISSOULA Until recently, little has been known about ... An international team of scientists, one of whom is ... breakthrough by showing that genes controlling the development of ... for rabbit domestication., The study was published Aug. 28 ... genetic questions. It is online at http://www.sciencemag.org/ ., ...
    (Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
    (Date:8/29/2014)... fold them: modern materials that are light, flexible and ... skin or electronic paper. , Making such concepts affordable ... new way of working with copper nanowires and a ... Previous success in the field of ultra-lightweight "aerogel monoliths" ... and silver nanowires. , By turning instead to ...
    Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2
    ... "Salt-loving algae could be the key to the successful ... means of recycling atmospheric carbon dioxide", Professor John Cushman ... General Microbiology meeting at Heriot-Watt University, Edinburgh, today (10 ... is the lack of adequate feedstocks, soybeans and corn, ...
    ... In Arctic areas, climate change is progressing faster than in ... Helsinki have participated in two new studies indicating that the ... are in jeopardy, as global warming causes species from southern ... of the original species. The renowned Science ...
    ... Research Council (ERC) expects to fund some 240 top ... This new wave of grantees follows the 299 researchers ... in 2007. In total, 2503 proposals were submitted ... Lehtonen,s research group is studying the kidney glomerular ultrafiltration ...
    Cached Biology News:The change in Arctic nature foreshadows the global environment of the future 2ERC Starting Grant for the researcher of kidney diseases 2
    GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
    ANTI 5-HYDROXYTRYPTOPHAN CONJ....
    ... use with T4 Polynucleotide Kinase for ... ends) of nucleic acids. In the ... the 5' phosphate group from DNA ... Gamma-phosphate of ATP to the free ...
    IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
    Biology Products: